The deal comes one day after the drugmaker announced it was entering late-stage testing for REGN-COV2, its experimental COVID-19 antibody treatment.
The trials are testing multiple dosages to discover the exact amount of treatment doses that should be produced. Regeneron estimates between 70,000 and 300,000 doses could become available, starting as soon as the end of summer.
More articles on pharmacy:
Novavax gets $1.6B from Operation Warp Speed to expedite COVID-19 vaccine development
Anthem PBM acquires pharmacy startup Zipdrug
Early use of hydroxychloroquine reduced COVID-19 deaths, study says
